Back to Search
Start Over
Breaking the barriers: Overcoming cancer resistance by targeting the NLRP3 inflammasome.
- Source :
-
British journal of pharmacology [Br J Pharmacol] 2025 Jan; Vol. 182 (1), pp. 3-25. Date of Electronic Publication: 2024 Oct 12. - Publication Year :
- 2025
-
Abstract
- Inflammation has a pivotal role in the initiation and progression of various cancers, contributing to crucial processes such as metastasis, angiogenesis, cell proliferation and invasion. Moreover, the release of cytokines mediated by inflammation within the tumour microenvironment (TME) has a crucial role in orchestrating these events. The activation of inflammatory caspases, facilitated by the recruitment of caspase-1, is initiated by the activation of pattern recognition receptors on the immune cell membrane. This activation results in the production of proinflammatory cytokines, including IL-1β and IL-18, and participates in diverse biological processes with significant implications. The NOD-Like Receptor Protein 3 (NLRP3) inflammasome holds a central role in innate immunity and regulates inflammation through releasing IL-1β and IL-18. Moreover, it interacts with various cellular compartments. Recently, the mechanisms underlying NLRP3 inflammasome activation have garnered considerable attention. Disruption in NLRP3 inflammasome activation has been associated with a spectrum of inflammatory diseases, encompassing diabetes, enteritis, neurodegenerative diseases, obesity and tumours. The NLRP3 impact on tumorigenesis varies across different cancer types, with contrasting roles observed. For example, colorectal cancer associated with colitis can be suppressed by NLRP3, whereas gastric and skin cancers may be promoted by its activity. This review provides comprehensive insights into the structure, biological characteristics and mechanisms of the NLRP3 inflammasome, with a specific focus on the relationship between NLRP3 and tumour-related immune responses, and TME. Furthermore, the review explores potential strategies for targeting cancers via NLRP3 inflammasome modulation. This encompasses innovative approaches, including NLRP3-based nanoparticles, gene-targeted therapy and immune checkpoint inhibitors.<br /> (© 2024 British Pharmacological Society.)
- Subjects :
- Humans
Animals
Drug Resistance, Neoplasm immunology
Antineoplastic Agents pharmacology
Antineoplastic Agents therapeutic use
Tumor Microenvironment immunology
NLR Family, Pyrin Domain-Containing 3 Protein metabolism
NLR Family, Pyrin Domain-Containing 3 Protein antagonists & inhibitors
NLR Family, Pyrin Domain-Containing 3 Protein immunology
Neoplasms drug therapy
Neoplasms immunology
Neoplasms metabolism
Neoplasms pathology
Inflammasomes metabolism
Inflammasomes immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1476-5381
- Volume :
- 182
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- British journal of pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 39394867
- Full Text :
- https://doi.org/10.1111/bph.17352